The state of gene therapies: the FDA perspective.
作者信息
Takefman Daniel, Bryan Wilson
出版信息
Mol Ther. 2012 May;20(5):877-8. doi: 10.1038/mt.2012.51.
Abstract
摘要
相似文献
1
The state of gene therapies: the FDA perspective.
Mol Ther. 2012 May;20(5):877-8. doi: 10.1038/mt.2012.51.
2
United States Food and Drug Administration Regulation of Gene and Cell Therapies.
Adv Exp Med Biol. 2015;871:1-29. doi: 10.1007/978-3-319-18618-4_1.
3
Gene-therapy trials must proceed with caution.
Nature. 2016 Jun 30;534(7609):590. doi: 10.1038/534590a.
4
Trials on trial.
Nature. 2008 May 22;453(7194):427-8. doi: 10.1038/453427b.
5
Drug approval: future aspects of the FDA.
Methods Find Exp Clin Pharmacol. 1998 Jul-Aug;20(6):527-37. doi: 10.1358/mf.1998.20.6.485716.
6
Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.
Cytotherapy. 2019 Jul;21(7):699-724. doi: 10.1016/j.jcyt.2019.04.002. Epub 2019 Jun 10.
7
European investigational antiepilepsy drug trials.
Epilepsy Res Suppl. 1993;10:149-55.
8
FDA perspective on clinical trial design for cardiovascular devices.
Ann Thorac Surg. 2006 Sep;82(3):773-5. doi: 10.1016/j.athoracsur.2006.07.044.
9
FDA penalizes trial misconduct.
Nat Biotechnol. 2009 Oct;27(10):872. doi: 10.1038/nbt1009-872.
10
FDA and drug approval.
J Vasc Interv Radiol. 1995 Nov-Dec;6(6 Pt 2 Suppl):24S. doi: 10.1016/s1051-0443(95)71244-1.
引用本文的文献
1
Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines.
Curr Gene Ther. 2024;25(1):10-21. doi: 10.2174/0115665232306205240419091414.
2
Peptide-Functionalized Dendrimer Nanocarriers for Targeted Microdystrophin Gene Delivery.
Pharmaceutics. 2021 Dec 15;13(12):2159. doi: 10.3390/pharmaceutics13122159.
3
Gene therapy for cancer: regulatory considerations for approval.
Cancer Gene Ther. 2015 Dec;22(12):554-63. doi: 10.1038/cgt.2015.58. Epub 2015 Nov 20.
4
Guanidinium-rich, glycerol-derived oligocarbonates: a new class of cell-penetrating molecular transporters that complex, deliver, and release siRNA.
Mol Pharm. 2015 Mar 2;12(3):742-50. doi: 10.1021/mp500581r. Epub 2015 Jan 27.
本文引用的文献
1
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
JAMA. 2011 Jun 8;305(22):2320-6. doi: 10.1001/jama.2011.769.
2
Pivotal studies of orphan drugs approved for neurological diseases.
Ann Neurol. 2009 Aug;66(2):184-90. doi: 10.1002/ana.21676.
3
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Science. 2003 Oct 17;302(5644):415-9. doi: 10.1126/science.1088547.
Zotero 插件